Aktis Oncology Q3 2026 net loss widens 93% to $29.9 million
AKTS•Aktis Oncology’s third-quarter net loss widened 93% year over year to $29.9 million. Collaboration revenue more than doubled to $3.9 million, and the company reported $492.9 million in cash, equivalents and marketable securities, expected to fund operations into 2029.
1. Quarterly results
Aktis Oncology’s third-quarter 2026 net loss widened 93% year over year to $29.9 million, primarily driven by higher operating expenses. Research and development expenses climbed 95% to $32.1 million, while collaboration revenue more than doubled to $3.9 million.
2. Cash and trials
Cash, cash equivalents and marketable securities totaled $492.9 million at September 30, 2026, which the company expects to fund operations into 2029. The Phase 1b BActinium-2 trial began evaluating AKY-2519 in non-small cell lung cancer and other B7-H3-expressing solid tumors. Preliminary AKY-1189 data are expected in the first quarter of 2027, with initial AKY-2519 results anticipated in 2027.
